Dr. Michael Bruner has more than 15 years of experience representing clients in pharmaceutical and chemical intellectual property matters, such as the development of global patent portfolios to protect their innovations. He guides clients from the early stages of patent portfolio development when leads are initially identified, continuing through the product development process as new filing opportunities arise.
Michael has a Ph.D. in organic chemistry and has extensive experience with patent matters pertaining to chemistry, biochemistry, and pharmaceuticals.
A particular focus of his practice is advising clients with respect to patent life-cycle strategies and regulatory extension opportunities as the portfolio matures and regulatory approval approaches. He also advises clients on due diligence matters, including those relating to clients' investment in or acquisition of third parties, as well as licensing and collaboration opportunities.
A further aspect of Michael's practice is providing clients with opinions relating to patentability, freedom-to-operate, noninfringement, and validity.
Representative clients include Celgene Corporation, PTC Therapeutics, Akebia Therapeutics, Hope Pharmaceuticals, Infinity Pharmaceuticals, Winpak Films, and Brasseler USA. Particular small molecule pharmaceuticals that Michael has been involved with include REVLIMID®, POMALYST®, TranslarnaTM, and Duvelisib. In particular, Michael has been involved with the preparation and prosecution of various patent filings relating to the compounds, as well as applications for U.S. and foreign regulatory extensions.
Prior to attending law school, Michael performed postdoctoral research at the Centers for Disease Control and Prevention (CDC) in the areas of vaccine and infectious diseases.
Evaluation of Synthetic, M type-specific Peptides as Antigens in a Multivalent Group A Streptococcal Vaccine, coauthor, Vaccine 21:2698
- May 2001
Multivalent Peptide Vaccine Against Group A Strep M Proteins Looks Promising, coauthor, Reuters Medical News
Use of an Altered Nucleotide Substrate to Unmask the Transition-State for Rat Liver a(2-6) Sialyltransferase, coauthor, Biochemistry 39:2261
Isotope Trapping and Kinetic Isotoope Effect Studies of Rat Liver a(2-6) Sialyltransferase, coauthor, Biochemistry 37:289
The N-Acetyl Neuraminyl Oxocarbenium Ion is an Intermediate in the Presence of Anionic Nucleophiles, coauthor, J. Am. Chem. Soc. 120:1357
Acid-Catalyzed Solvolysis of CMP-NeuAc: Evidence for a Sialyl Cation with a Finite Lifetime, coauthor, J. Am. Chem. Soc. 118:10371
- Fordham University (J.D. cum laude 2005; awarded 2005 Benjamin Finkel Prize for excellence in bankruptcy); Centers for Disease Control and Prevention, Atlanta (American Society for Microbiology Postdoctoral Research Fellowship in the areas of vaccine and infectious diseases, 1999-2001); University of Florida, Gainesville (Ph.D. 1999 under the guidance of Dr. Ben Horenstein); University of West Florida, Pensacola (B.S. in Chemistry 1994)
- Georgia, New York, and registered to practice before the United States Patent and Trademark Office